Bevacizumab biosimilar (North China Pharmaceutical)

贝伐珠单抗生物类似药（华北制药）

Report date: 2022/07/08 16:29:06

Base Information

Drug NameBevacizumab biosimilar (North China Pharmaceutical)
Drug Alias Name重组抗人血管内皮生长因子单克隆抗体注射液Recombinant anti-VEGF monoclonal antibody (North China Pharmaceutical)MG-021
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsMacular DegenerationCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNorth China Pharmaceutical Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNorth China Pharmaceutical Group New Drug R&D Co Ltd
Inactive CompaniesN/A
Active IndicationsMacular DegenerationCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A